ExCellThera announces new publication showing its ECT-001 cell therapy improves transplant access for all patients
April 13, 2022 08:05 ET
|
ExCellThera
MONTREAL, April 13, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera announces new data to be presented at the EBMT 2022 annual meeting
March 15, 2022 08:04 ET
|
ExCellThera
MONTRÉAL, March 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand...
ExCellThera announces first patient treated in Phase I/II trial of ECT-001 cell therapy for pediatric patients with high risk blood cancer
March 10, 2022 08:04 ET
|
ExCellThera
MONTREAL, March 10, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and...
ExCellThera announces settlement of its patent infringement claims against Selleck Chemicals
December 21, 2021 08:05 ET
|
ExCellThera
MONTRÉAL, Dec. 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting
November 29, 2021 08:05 ET
|
ExCellThera
MONTRÉAL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
ExCellThera and Astellas enter into a license for the use of molecule UM171 in the field of pluripotent stem cells
July 13, 2021 08:05 ET
|
ExCellThera
MONTREAL, July 13, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune...
Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health
April 21, 2021 08:02 ET
|
ExCellThera
MONTREAL, April 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells...
ExCellThera announces UM171 mechanism of action
January 07, 2021 11:15 ET
|
ExCellThera
MONTRÉAL, Jan. 07, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera receives Priority Medicines (PRIME) designation from European Medicines Agency for ECT-001 Cell Therapy
December 11, 2020 07:55 ET
|
ExCellThera
MONTREAL, Dec. 11, 2020 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for...
ExCellThera announces publication in The Lancet Haematology highlighting excellent clinical results of ECT-001 in patients with haematological malignancies
November 06, 2019 07:00 ET
|
ExCellThera
MONTREAL, Nov. 06, 2019 (GLOBE NEWSWIRE) -- ExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use,...